After 11 years in pharma commercial strategy, I’ve sat through enough keynote speeches to fill a stadium—and I can count on one hand the number of those moments that actually led to a signed contract or a change in formulary status. In this industry, we suffer from “event bloat.” We attend conferences because we’re told they are “must-attend” (a phrase I despise), but we rarely walk away with a tangible shift in market access.
If your strategy is to show up, hand out business cards, and hope for organic growth, you aren’t running a commercial strategy; you’re running a hobby. To gain traction in oncology—a space where clinical pathway inclusion is the difference between a successful launch and a quiet failure—you need a surgical approach to your conference portfolio.
The Annual Portfolio: Anchoring Your Strategy
Successful commercial teams don’t pick events based on the glitz of the venue or the speaker lineup. They build a calendar based on the *product lifecycle* and *strategic objectives*. If you aren’t mapping your event presence to your quarterly commercial milestones, you are wasting your budget.
I organize my year into three distinct strategic buckets:
- The Summer Anchor (BIO Partnering Platform): This is your pulse check on the innovation landscape. It isn’t just for licensing deals; it’s for understanding the competitive pipeline and identifying partners who are actually moving the needle. The Commercial Execution Layer (Fierce Pharma Week): This is where you stress-test your commercial execution. It’s for benchmarking your competitive intelligence (CI) and ensuring your sales and marketing messaging isn’t just echoing your competitors. The Formulary Reality Layer (The Health Management Academy - THMA Forums): This is where the rubber hits the road. This is not about marketing; it’s about understanding the internal mechanisms of health systems and the real-world barriers to oncology adoption.
Why THMA Forums are the Only Place for Formulary Reality
Let’s get specific. In oncology, your biggest hurdle isn’t just "awareness"—it’s formulary positioning and clinical pathway inclusion. If a clinical pathway at a top-tier IDN (Integrated Delivery Network) excludes your drug, you are fighting an uphill battle against geography and protocol.
Many conferences offer “access to decision-makers,” which usually means you stand in a lobby hoping to bump into a Pharmacy Director. THMA forums function differently. They are designed to bring health system leaders—the people who actually sit on P&T (Pharmacy & Therapeutics) committees—into a space where the conversation revolves around the operational realities of delivering cancer care.
Breaking Down Oncology Adoption Barriers
The barrier to oncology adoption isn't just clinical efficacy; it's the administrative burden of your drug. Does it require a complex prior authorization? Is it easy to administer in an outpatient infusion setting? Does it integrate with the health system’s existing electronic health records (EHR)?
At a THMA forum, you stop pitching and start listening. You gain insights into:
- Pathway Logic: How are the system’s oncologists weighing clinical value against the cost of care? Resource Constraints: Does your drug require specific pharmacy staffing or monitoring that the health system currently lacks? Internal Policy: How does the system prioritize innovative therapies vs. biosimilars or standard-of-care agents?
This is where "formulary positioning" moves from a slide deck to a tactical plan. If you learn at a forum that a major IDN is struggling with the clinical pathway inclusion of high-cost agents due to specific billing code gaps, you have a concrete problem to solve with your Market Access team before you walk into their office the next Monday.
Comparison: Measuring the Value of Your Portfolio
Not all conferences serve the same purpose. The following table illustrates how I evaluate the meetings in my portfolio to avoid the trap of "meetings that look big but do nothing."
Event Type Primary Objective Outcome Measure The "Trap" to Avoid BIO Partnering Pipeline Intelligence Number of high-potential assets/partners identified. Treating it as a "general networking" event. Fierce Pharma Week Commercial Execution Benchmarking CI against internal sales goals. Falling for vendor-heavy sales pitches. THMA Forums Formulary/Pathways Actionable insights on P&T hurdles/barriers. Expecting immediate contracts during sessions.
The Goal-First Checklist: How to Plan Your Attendance
Stop looking at conference websites and start looking at your 12-month commercial strategy. Before worldpharmatoday.com you register for anything, run your intended attendance through this checklist. If you can't answer these questions, don't go.
What is the specific access barrier we are trying to solve? (e.g., "We are missing from the IDN pathway in the Northeast"). Who is the specific individual at the conference who can provide that data? (Don't list "thought leaders." List "The Chair of the Oncology P&T Committee for System X"). What happens the Monday after? (What is the exact deliverable that the team is expected to produce based on the intelligence gathered at the event?) Does this meeting replicate information I can get via standard competitive intelligence reports? (If the answer is yes, save your time and your budget).The "No-Hype" Conclusion
I have spent a career watching teams get distracted by the "event brand"—the bright lights, the celebrity keynote speakers, and the high-production-value vendor booths. None of that helps you get onto a clinical pathway.
For oncology commercial leads, the real work happens in the quiet, specific conversations at forums like THMA, where you are tasked with understanding how to lower the barriers to entry for your drug. It’s not about being the loudest person in the room; it’s about being the most informed person regarding the systems that hold the keys to your adoption.
Stop chasing the big-name conferences just to fill a seat. Start building a portfolio that actually solves the formulary problems standing in the way of your patients. Your commercial trajectory depends on it.